IMNM
NASDAQ HealthcareImmunome, Inc. - Common Stock
Biotechnology
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
�� 市场数据
| 价格 | $23.97 |
|---|---|
| 成交量 | 3,922,095 |
| 市值 | 2.72B |
| 贝塔系数 | 2.130 |
| RSI（14日） | 15.1 超卖 |
| 200日均线 | $22.61 |
| 50日均线 | $25.29 |
| 52周最高 | $30.06 |
| 52周最低 | $9.28 |
| Forward P/E | -9.67 |
| Price / Book | 5.18 |
🎯 投资策略评分
IMNM 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🚀 Moon Shot (96/100) — 此策略 高增长潜力（高贝塔 + 超卖）.
评分最低的策略： 🎈 Over-Hyped (4/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 IMNM in your text
粘贴任何文章、记录或帖子 — 工具将提取 IMNM 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-09-18.